Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOPAC: Neoadjuvant Gemcitabine/Oxaliplatin in Pancreatic Cancer
NCT01314027Phase 3Terminated
- Sponsor
- University of Zurich
- Start
- Sep 2009
- Primary completion
- Dec 2018
- Modality
- DNA Intercalators/Alkylators
- Countries
- 4
01
Overview
A Phase 3 trial of oxaliplatin in pancreatic cancer (PC), sponsored by University of Zurich. Started Sep 2009; status: terminated.
02
Drugs
oxaliplatin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT01314027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01314027.